Daphne Ruth Friedman, MD

Associate Professor of Medicine
Member of the Duke Cancer Institute
Campus mail 508 Fulton Street (111g), Durham VA Medical Center, Durham, NC 27705
Phone (919) 286-6944
Email address daphne.friedman@duke.edu

My area of expertise is in leukemias and lymphomas, including Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. My research interests are focused on improving treatment options for patients with hematologic malignancies, through laboratory and clinical research.  I am also a staff physician at the Durham VA Medical Center, and am deeply committed to expanding treatment options for veterans, including working on clinical trials for multiple myeloma, prostate cancer, and lung cancer at the Durham VA.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 2005 - 2008
  • Medical Resident, Medicine, University of Maryland, College Park, 2002 - 2005
  • M.D., University of Maryland, College Park, 2002

Publications

Chanfreau, C, Lynch, KE, Chang, JW, Becker, DJ, Friedman, DR, Rivera, DR, DuVall, SL, and Lynch, JA. "Chronic myeloid leukemia among veterans from 2006 to 2015: Trends in utilization of tyrosine kinase inhibitors.": WILEY, August 1, 2018.

Scholars@Duke

Chanfreau, C, Lynch, KE, Chang, JW, Becker, DJ, Friedman, DR, Rivera, DR, DuVall, SL, and Lynch, JA. "Chronic myeloid leukemia among veterans from 2006 to 2015: Trends in utilization of tyrosine kinase inhibitors.": WILEY, August 1, 2018.

Scholars@Duke

Friedman, DR. "Lipids and Their Effects in Chronic Lymphocytic Leukemia." EBioMedicine 15 (February 2017): 2-3. (Letter)

PMID
27988133
Full Text

Friedman, DR, Guadeloupe, E, Volkheimer, A, and Weinberg, JB. "Surface CD5 Protein Risk Stratifies Chronic Lymphocytic Leukemia." 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). San Diego, CA. December 3, 2016 - December 6, 2016.: AMER SOC HEMATOLOGY, December 2, 2016.

Scholars@Duke

Friedman, DR, Sibley, AB, Owzar, K, Chaffee, KG, Slager, S, Kay, NE, Hanson, CA, Ding, W, Shanafelt, TD, Weinberg, JB, and Wilcox, RA. "Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study." American Journal of Hematology 91, no. 7 (July 2016): 687-691.

PMID
27037726
Full Text

Vakkalanka, S, Penmetsa, KV, Chasse, D, Chen, Y, Viswanadha, S, Friedman, DR, and Weinberg, JB. "Abstract A24: The dual PI3K δ/γ inhibitor, RP6530, in combination with ibrutinib or fludarabine, synergistically enhances cytotoxicity in primary CLL cells in vitro." September 1, 2015.

Full Text

Holohan, B, Hagiopian, MM, Lai, T-P, Huang, E, Friedman, DR, Wright, WE, and Shay, JW. "Perifosine as a potential novel anti-telomerase therapy." Oncotarget 6, no. 26 (September 2015): 21816-21826.

PMID
26307677
Full Text

Friedman, DR, Stewart, T, Guadalupe, E, Brander, DM, Pisetsky, DS, and Weinberg, JB. "Pan-caspase peptide inhibitor to induce primary chronic lymphocytic leukemia (CLL) cell death through a non-apoptotic and non-necroptotic mechanism." May 20, 2015.

Scholars@Duke

Rempel, RE, Jiang, X, Fullerton, P, Tan, TZ, Ye, J, Lau, JA, Mori, S, Chi, J-T, Nevins, JR, and Friedman, DR. "Utilization of the Eμ-Myc mouse to model heterogeneity of therapeutic response." Molecular Cancer Therapeutics 13, no. 12 (December 2014): 3219-3229.

PMID
25349303
Full Text

Friedman, DR, Simms, T, Allgood, SD, Brander, DM, Sportelli, P, Miskin, HP, Vakkalanka, S, Viswanadha, S, Weinberg, JB, and Lanasa, MC. "Abstract 4518: The PI3K-δ inhibitor TGR-1202 induces cytotoxicity and inhibits phosphorylation of AKT in 17p deleted and non-17p deleted CLL cells in vitro." October 1, 2014.

Full Text

Pages